162 related articles for article (PubMed ID: 33663205)
1. Uncovering the Effect of pS202/pT205/pS208 Triple Phosphorylations on the Conformational Features of the Key Fragment G192-T212 of Tau Protein.
Liu H; Li Q; Xiong C; Zhong H; Zhang Q; Liu H; Yao X
ACS Chem Neurosci; 2021 Mar; 12(6):1039-1048. PubMed ID: 33663205
[TBL] [Abstract][Full Text] [Related]
2. Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8.
Malia TJ; Teplyakov A; Ernst R; Wu SJ; Lacy ER; Liu X; Vandermeeren M; Mercken M; Luo J; Sweet RW; Gilliland GL
Proteins; 2016 Apr; 84(4):427-34. PubMed ID: 26800003
[TBL] [Abstract][Full Text] [Related]
3. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.
Augustinack JC; Schneider A; Mandelkow EM; Hyman BT
Acta Neuropathol; 2002 Jan; 103(1):26-35. PubMed ID: 11837744
[TBL] [Abstract][Full Text] [Related]
4. Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation.
Aragão Gomes L; Uytterhoeven V; Lopez-Sanmartin D; Tomé SO; Tousseyn T; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Verstreken P; Thal DR
Acta Neuropathol; 2021 Feb; 141(2):173-192. PubMed ID: 33427938
[TBL] [Abstract][Full Text] [Related]
5. Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau.
Landrieu I; Smet-Nocca C; Amniai L; Louis JV; Wieruszeski JM; Goris J; Janssens V; Lippens G
PLoS One; 2011; 6(6):e21521. PubMed ID: 21731772
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation at Ser289 Enhances the Oligomerization of Tau Repeat R2.
Man VH; He X; Han F; Cai L; Wang L; Niu T; Zhai J; Ji B; Gao J; Wang J
J Chem Inf Model; 2023 Feb; 63(4):1351-1361. PubMed ID: 36786552
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tau self-aggregation and neurotoxicity.
Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
[TBL] [Abstract][Full Text] [Related]
8. Disclosing the Mechanism of Spontaneous Aggregation and Template-Induced Misfolding of the Key Hexapeptide (PHF6) of Tau Protein Based on Molecular Dynamics Simulation.
Liu H; Zhong H; Liu X; Zhou S; Tan S; Liu H; Yao X
ACS Chem Neurosci; 2019 Dec; 10(12):4810-4823. PubMed ID: 31661961
[TBL] [Abstract][Full Text] [Related]
9. Tau as a therapeutic target for Alzheimer's disease.
Boutajangout A; Sigurdsson EM; Krishnamurthy PK
Curr Alzheimer Res; 2011 Sep; 8(6):666-77. PubMed ID: 21679154
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulation of the phosphorylation-induced conformational changes of a tau peptide fragment.
Lyons AJ; Gandhi NS; Mancera RL
Proteins; 2014 Sep; 82(9):1907-23. PubMed ID: 24577753
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation-Induced Structural Reorganization in Tau-Paired Helical Filaments.
Rani L; Mallajosyula SS
ACS Chem Neurosci; 2021 May; 12(9):1621-1631. PubMed ID: 33877805
[TBL] [Abstract][Full Text] [Related]
12. Conformation and Affinity Modulations by Multiple Phosphorylation Occurring in the BIN1 SH3 Domain Binding Site of the Tau Protein Proline-Rich Region.
Lasorsa A; Bera K; Malki I; Dupré E; Cantrelle FX; Merzougui H; Sinnaeve D; Hanoulle X; Hritz J; Landrieu I
Biochemistry; 2023 Jun; 62(11):1631-1642. PubMed ID: 37167199
[TBL] [Abstract][Full Text] [Related]
13. On the Tracks of the Aggregation Mechanism of the PHF6 Peptide from Tau Protein: Molecular Dynamics, Energy, and Interaction Network Investigations.
Fagnen C; Giovannini J; Catto M; Voisin-Chiret AS; Sopkova-de Oliveira Santos J
ACS Chem Neurosci; 2022 Oct; 13(19):2874-2887. PubMed ID: 36153969
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the Effect of Lysine Acetylation on the Misfolding and Aggregation of Human Tau Fragment
Shah SJA; Zhong H; Zhang Q; Liu H
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269542
[TBL] [Abstract][Full Text] [Related]
15. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
[TBL] [Abstract][Full Text] [Related]
16. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
17. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design.
Wang D; Huang X; Yan L; Zhou L; Yan C; Wu J; Su Z; Huang Y
Protein J; 2021 Oct; 40(5):656-668. PubMed ID: 34401998
[TBL] [Abstract][Full Text] [Related]
18. Tau (297-391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer's disease brain.
Al-Hilaly YK; Foster BE; Biasetti L; Lutter L; Pollack SJ; Rickard JE; Storey JMD; Harrington CR; Xue WF; Wischik CM; Serpell LC
FEBS Lett; 2020 Mar; 594(5):944-950. PubMed ID: 31721178
[TBL] [Abstract][Full Text] [Related]
19. Posttranslational modifications of tau in paired helical filaments.
Morishima M; Ihara Y
Dementia; 1994; 5(5):282-8. PubMed ID: 7951685
[TBL] [Abstract][Full Text] [Related]
20. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Wang JZ; Grundke-Iqbal I; Iqbal K
Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
